surmount-1 tirzepatide non-diabetic obesity trial Read now: The SURPASS-EARLY found that starting #tirzepatide early in #type2diabetes led to greater improvements in blood sugar, body weight, and waist size than intensified standard care. https://bit.ly/3RWnB8m tirzepatide trial obesity without diabetes

At the index date in GLP-1 RA vs SGLT-2 inhibitor cohort, GLP-1 RA users were generally younger (median age 55 years [25-75 percentile: 45-65] vs 66 years [25-75 percentile: 57-74] more often female (59% vs 36%) and had a higher level of education compared with SGLT-2 inhibitor users (21% vs 15% were within ISCED level 6-8)

Often referred to as the Triple G agonist, this compound goes a step beyond current market leaders like Semaglutide and Tirzepatide by targeting three distinct hormonal pathways simultaneously

However, mild side effects may occur during the initial adjustment period

Accidentally injecting into muscle (intramuscular) or very shallow into the skin (intradermal) can affect how the drug is absorbed

"Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes." JAMA Netw Open